As US and Canadian firms report their latest quarterly results, which began with Procter & Gamble on 23 January (see story above) and continues with Church & Dwight Co. Inc. on 2 February, investors will learn whether the latest supply chain disruption is affecting the consumer health sector’s results, or it will affect them later in 2024.
Key Takeaways
- In November, Perrigo reported third-quarter net sales growing 2.2% to $1.1bn, or 1.2% on an organic measure including a loss of 2.8 percentage points from stock-keeping unit trimming included in its supply chain reinvention and shifts in distribution of HRA Pharma products after acquiring the French women’s health and personal care products firm in 2022. Its consumer health product net sales in the Americas region were off 2.6% from the prior-year period at $703.5m but up more than 11% in international markets to $420.3m. Total net sales, including Rx products from HRA Pharma and others Perrigo still owns, were $1.123bn. It boosted its full-year 2023 guidance while announcing third-quarter reported earnings per share of 11 cents after posting a 39-cent per share loss in the prior-ago period. (Also see "Perrigo Results Reach A Valley Before Peak Expected From Opill Launch, Private Label Gains" - HBW Insight, 8 November, 2023.)
As US and Canadian firms report their latest quarterly results, which began with Procter & Gamble on 23 January (see...
